Phaseline

Companies › Coherus Oncology

Coherus Oncology: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Casdozokitug
Soluble guanylate cyclase stimulator
GUCY1A1, GUCY1B1Phase 2Hepatocellular CarcinomaSep 2027
CHS-114–Phase 1Advanced Solid Tumor; Metastatic Solid TumorJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05635643CHS-114Phase 1Advanced Solid TumorOncologyJan 2027
NCT06679985CasdozokitugPhase 2Hepatocellular CarcinomaOncologySep 2027
NCT06657144CHS-114Phase 1Metastatic Solid TumorOncologyJan 2028

From the company's SEC filings

Cash and short-term investments of $84m on 2026-09-30; operating cash outflow about $207m a year; runway about 5 months at that burn, to Feb 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GUCY1A1 (1) GUCY1B1 (1)

Companies with the same targets

Merck & Co. (MSD) Pulmovant Kardigan Bayer Akebia Therapeutics

Companies built like this

Neonc Technologies Agenus Lantern Pharma Innate Pharma Oncolytics Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.